A synbiotic for regulating protein allergy, an infant amino acid formula powder, and its preparation method

Abstract

This invention provides a synbiotic for regulating protein allergy, an infant amino acid formula powder, and its preparation method, belonging to the field of milk powder technology. A synbiotic for regulating protein allergy comprises the following components in parts by weight: 10-30 parts of galactooligosaccharides, 1-3 parts of fructooligosaccharides, 5-15 parts of 2'-fucosylated lactose, 1-3 parts of lactose-N-neotetrasaccharide, 1-2 parts of sodium 3'-sialotyl-lactose, and 0.1-5 parts of Bifidobacterium longum subsp. infantis M-63. The synbiotic components work synergistically to deeply mimic the mechanisms of action of breast milk in building intestinal microecology, regulating immune function, and promoting digestive comfort. Combined with amino acids, nucleotides, and other nutrients, this formula is formulated into an infant amino acid formula powder, which can effectively reduce allergy symptoms and reactions, providing a scientific nutritional solution that closely approximates the physiological benefits of breast milk for allergic infants who cannot be breastfed.

Description

Technical Field

[0001] This invention belongs to the field of milk powder technology, specifically relating to a synbiotic for regulating protein allergies, an infant amino acid formula powder, and its preparation method. Background Technology

[0002] The incidence of allergic diseases in infants and young children is on the rise globally, becoming a significant public health issue affecting their healthy growth. For infants diagnosed with food protein allergies, dietary avoidance is currently the most basic and effective management strategy. However, infants and young children are in a period of rapid growth and development, with extremely high requirements for energy and various nutrients. Therefore, while avoiding allergens, it is crucial to provide these children with a special medical purpose formula that can completely replace regular formula milk powder, is nutritionally complete, and is absolutely safe.

[0003] While extensively hydrolyzed protein formula (eHF) is the first choice for most children with mild to moderate CMPA (cow's milk protein allergy), it still contains short-chain peptides. For some infants with severe allergies, multiple food allergies, or severe gastrointestinal symptoms (such as eosinophilic esophagitis or protein-losing enteropathy), there remains a risk of sensitization or poor efficacy. Amino acid formula powders are more thoroughly hypoallergenic than extensively hydrolyzed formulas and are suitable for a wider range of people; however, the variety of amino acid formula products is limited and the price is higher, making it difficult to meet the needs of a broad range of clinical and family patients. Summary of the Invention

[0004] The purpose of this invention is to provide a synbiotic for regulating protein allergies, which combines traditional prebiotics, human milk oligosaccharides, and probiotics to deeply mimic the core mechanisms of breast milk in building intestinal microecology, regulating immune function, and promoting digestive comfort through synergistic effects, thus providing a new approach for allergic infants who cannot accept breastfeeding.

[0005] This invention provides a synbiotic for regulating protein allergy, comprising the following components in parts by weight: Galacto-oligosaccharides (GOS) 10-30 parts, fructooligosaccharides (FOS) 1-3 parts, 2'-fucosylated lactose (2'-FL) 5-15 parts, lactose-N-neotetrasaccharide (LNnT) 1-3 parts, 3'-sialic acid lactose sodium salt (3'-SL) 1-2 parts, and Bifidobacterium longum subsp. infantis M-63 0.1-5 parts.

[0006] Preferably, the components include the following parts by weight: 15-20 parts of galactooligosaccharide, 1.5-2.5 parts of fructooligosaccharide, 7-10 parts of 2'-fucosylated lactose, 2.5-3.0 parts of lactose-N-neotetrasaccharide, 1.2-1.6 parts of sodium 3'-sialylated lactose, and 0.5-1.2 parts of Bifidobacterium longum subsp. infantis M-63.

[0007] Preferably, the components include the following parts by weight: 18 parts of galactooligosaccharide, 2.0 parts of fructooligosaccharide, 8 parts of 2'-fucosylated lactose, 2.7 parts of lactose-N-neotetrasaccharide, 1.4 parts of sodium 3'-sialylated lactose, and 1 part of Bifidobacterium longum subsp. infantis M-63.

[0008] This invention provides an amino acid formula powder for infants and young children that regulates protein allergy, comprising the aforementioned synbiotic and the following components in parts by weight: 500-700 parts vegetable fat powder, 130-160 parts compound amino acids, 110-140 parts solid corn syrup, 40-60 parts compound minerals, 10-30 parts choline premix, 5-15 parts arachidonic acid, 2.5-7.5 parts docosahexaenoic acid, 2.5-7.5 parts compound vitamins, and 0.20-0.40 parts nucleotides; One part by weight of the ingredients is based on one part by weight of Bifidobacterium longum subsp. infantis M-63.

[0009] Preferably, the ingredients include the following components in parts by weight: 580-620 parts vegetable fat powder, 145-155 parts compound amino acids, 120-130 parts solid corn syrup, 45-55 parts compound minerals, 15-25 parts choline premix, 8-12 parts arachidonic acid, 4-6 parts docosahexaenoic acid, 4-6 parts compound vitamins, and 0.28-0.35 parts nucleotides.

[0010] Preferably, based on 1000 parts by weight of infant amino acid formula powder, the compound amino acid comprises the following components in parts by weight: 10-40 parts L-glutamine, 10-40 parts L-leucine, 10-40 parts L-lysine acetate, 10-40 parts L-aspartic acid, 5-35 parts L-proline, 5-35 parts L-isoleucine, 5-35 parts L-valine, 5-35 parts L-tyrosine, 5-25 parts L-threonine, 1-20 parts L-phenylalanine, 1-20 parts L-serine, 1-20 parts L-alanine, 1-20 parts L-histidine, 1-20 parts L-arginine, 1-20 parts glycine, 1-15 parts L-cysteine, 1-15 parts L-tryptophan, and 1-10 parts L-methionine.

[0011] Preferably, based on 1000 parts by weight of infant amino acid formula powder, the vegetable fat powder comprises the following components in parts by weight: 170-250 parts of solid corn syrup, 80-120 parts of maltodextrin, 55-85 parts of medium-chain triglycerides, 50-70 parts of 1,3-dioleoyl-2-palmitoyl triglycerides, 40-60 parts of coconut oil, 42-57 parts of sunflower seed oil, 1-10 parts of flaxseed oil, 1-10 parts of mono- and diglycerides of fatty acids, 30-50 parts of sodium octenyl succinate starch, 0.5-2.0 parts of sodium L-ascorbate, 0.01-0.1 parts of mixed tocopherol concentrate, and 0.01-0.05 parts of ascorbate palmitate.

[0012] The compound minerals comprise the following components by weight: potassium 5-6.75 parts, magnesium 0.457-0.618 parts, iron 0.0585-0.079 parts, zinc 0.053-0.072 parts, calcium 4.01-5.43 parts, selenium 0.0002025-0.000304 parts, sodium 0.95-1.29 parts, phosphorus 2.51-3.395 parts, chlorine 3.36-4.545 parts, chromium 0.0001215-0.000198 parts, manganese 0.00255-0.00425 parts, and copper 0.003315-0.005525 parts; The choline premix comprises the following components by weight: 0.516-0.696 parts inositol, 0.36-0.49 parts taurine, 0.1636-0.2214 parts choline, and 1.676-2.268 parts L-carnitine; The compound vitamins comprise the following components by weight: Vitamin A 0.004685~0.00634 parts, Vitamin D3 0.000146~0.000219 parts, Vitamin K1 0.000625~0.000845 parts, Vitamin B1 0.00635~0.0086 parts, Vitamin B2 0.0089~0.012 parts, Vitamin B6 0.0053~0.0072 parts, Niacin 0.047~0.064 parts, Folic Acid 0.00097~0.001315 parts, Pantothenic Acid 0.03925~0.0531 parts, Biotin 0.000145~0.000217 parts, Vitamin C 1.405~1.9 parts, Vitamin E 0.1035~0.1395 parts, Vitamin B12 0.00001575~0.00002625 parts and iodine 0.00107~0.00178 parts; The nucleotides comprise the following components in parts by weight: 0.01-0.2 parts of 5'-adenosine monophosphate, 0.05-0.2 parts of 5'-cytidine monophosphate, 0.05-0.15 parts of disodium 5'-uridine monophosphate, 0.01-0.1 parts of disodium 5'-guanylate, and 0.001-0.02 parts of disodium 5'-inosinate.

[0013] This invention provides a method for preparing the aforementioned infant amino acid formula powder, comprising the following steps: A portion of solid corn syrup, Bifidobacterium longum subsp. infantis M-63, 3'-sialic acid lactose sodium nucleotide, fructooligosaccharide, lactose-N-neotetrasaccharide, compound vitamins, compound minerals and docosahexaenoic acid were dry premixed to obtain the first mixture. The premix, the remaining solid corn syrup, 2'-fucosylated lactose, arachidonic acid, galactooligosaccharides, choline premix, and compound amino acids are dry-mixed to obtain a second mixture; The second mixture and vegetable fat powder are dry-mixed to obtain an infant amino acid formula powder.

[0014] This invention provides the application of the synbiotic in the preparation of amino acid formula powder for infants with protein allergies.

[0015] Preferably, the infants include individuals allergic to at least one of food proteins, breast milk proteins, and extensively hydrolyzed formula milk powder.

[0016] This invention provides a synbiotic for regulating protein allergy, comprising the following components in parts by weight: 10-30 parts of galactooligosaccharides, 1-3 parts of fructooligosaccharides, 5-15 parts of 2'-fucosylated lactose, 1-3 parts of lactose-N-neotetrasaccharide, 1-2 parts of sodium 3'-sialotyl-lactose, and 0.1-5 parts of Bifidobacterium longum subsp. infantis M-63. This invention combines two prebiotics (GOS+FOS), three key human milk oligosaccharides (2'-FL+LNnT+3'-SL), and Bifidobacterium longum subsp. infantis M-63 to form a synbiotic. Through the specific combination of the above components, this synbiotic can deeply mimic the effects of breast milk in constructing the intestinal microecology, regulating immune function, and promoting digestive comfort, thereby exerting a synergistic effect. In animal experiments, the efficacy of different groups in inhibiting allergies was evaluated by detecting four indicators: IgE, IgG1, mMCP-1, and allergy symptom scores. Compared with the traditional prebiotic composition group and the prebiotic mixture group, the synbiotic showed the best performance in alleviating allergy symptoms. Furthermore, removing any human milk oligosaccharide (2'-FL, LNnT, 3'-SL) from the complete synbiotic formula led to a decrease in the overall protective effect, indicating that each human milk oligosaccharide (HMO) contributes to inhibiting the complete allergy chain. Meanwhile, in vitro simulation experiments showed that, compared with the traditional prebiotic composition group and the prebiotic mixture group, the synbiotic increased the content of short-chain fatty acids (acetic acid, propionic acid, butyric acid) in the intestinal flora fermentation broth. Analysis suggests this may be because the prebiotic mixture provided a richer fermentation substrate for the intestinal flora, while the addition of strain M-63 to the prebiotic mixture further synergistically promoted the metabolic activity of acid-producing bacteria. Regarding the effect on Bifidobacterium abundance, compared with the traditional prebiotic composition group, the synbiotic significantly increased the relative abundance of Bifidobacterium, followed by the prebiotic mixture group. The addition of Bifidobacterium longum subsp. infantis M-63 to the synbiotic, combined with the prebiotic mixture (which mimics the structure of human milk oligosaccharides), achieved efficient colonization and proliferation of the intestinal flora, forming a synergistic effect.

[0017] This invention provides an amino acid formula powder for infants with protein allergies, comprising the aforementioned synbiotic and the following components by weight: 500-700 parts vegetable fat powder, 130-160 parts compound amino acids, 110-140 parts solid corn syrup, 40-60 parts compound minerals, 10-30 parts choline premix, 5-15 parts arachidonic acid, 2.5-7.5 parts docosahexaenoic acid, 2.5-7.5 parts compound vitamins, and 0.20-0.40 parts nucleotides. The combination of the synbiotic, vegetable fat powder, compound amino acids, various fatty acids, compound vitamins, nucleotides, and other nutrients can effectively alleviate allergy symptoms in infants sensitive to protein, providing a scientific nutritional solution that closely approximates the physiological benefits of breast milk for allergic infants who cannot be breastfed. Detailed Implementation

[0018] This invention provides a synbiotic for regulating protein allergy, comprising the following components in parts by weight: 10-30 parts of galactooligosaccharide (GOS), 1-3 parts of fructooligosaccharide (FOS), 5-15 parts of 2'-fucosylated lactose (2'-FL), 1-3 parts of lactose-N-neotetrasaccharide (LNnT), 1-2 parts of sodium 3'-sialylated lactose (3'-SL), and 0.1-5 parts of Bifidobacterium longum subsp. infantis M-63.

[0019] In this invention, the synbiotic preferably comprises the following components in parts by weight: 15-20 parts of galactooligosaccharide, 1.5-2.5 parts of fructooligosaccharide, 7-10 parts of 2'-fucosylated lactose, 2.5-3.0 parts of lactose-N-neotetrasaccharide, 1.2-1.6 parts of sodium 3'-sialotrol, and 0.8-1.2 parts of Bifidobacterium longum subsp. infantis M-63; alternatively, it may consist of 18 parts of galactooligosaccharide, 2.0 parts of fructooligosaccharide, 8 parts of 2'-fucosylated lactose, 2.7 parts of lactose-N-neotetrasaccharide, 1.4 parts of sodium 3'-sialotrol, and 1 part of Bifidobacterium longum subsp. infantis M-63. The galactooligosaccharide and fructooligosaccharide are traditional prebiotics. The 2'-fucosylated lactose, lactose-N-neotetrasaccharide, and sodium 3'-sialotrol are human milk oligosaccharides. The combination of traditional prebiotics, human milk oligosaccharides, and highly active probiotics (Bifidobacterium longum subsp. infantis M-63) achieves a synergistic effect, which helps to deeply mimic the mechanisms by which breast milk constructs the intestinal microecology, regulates immune function, and promotes digestive comfort, thereby reducing allergy symptoms and inhibiting allergic reactions. The inhibition of allergic reactions includes reducing the levels of IgE, IgG1, and mMCP-1, most effectively blocking allergy initiation (inhibiting IgE), strongly correcting Th2 immune shift (significantly reducing IgG1), and thus maximally inhibiting the terminal effect (significantly reducing mMCP-1). This invention does not impose any special restrictions on the source of the above components; any component source well known in the art may be used.

[0020] This invention provides an amino acid formula powder for infants and young children to regulate protein allergies, comprising the aforementioned synbiotic and the following components in parts by weight: 500-700 parts of vegetable fat powder, 130-160 parts of compound amino acids, 110-140 parts of solid corn syrup, 40-60 parts of compound minerals, 10-30 parts of choline premix, 5-15 parts of arachidonic acid, 2.5-7.5 parts of docosahexaenoic acid, 2.5-7.5 parts of compound vitamins, and 0.20-0.40 parts of nucleotides; wherein 1 part of the components is based on 1 part by weight of Bifidobacterium longum subsp. infantis M-63.

[0021] In this invention, the infant amino acid formula powder preferably comprises the following components in parts by weight: 580-620 parts of vegetable fat powder, 145-155 parts of compound amino acids, 115-135 parts of solid corn syrup, 45-55 parts of compound minerals, 15-25 parts of choline premix, 8-12 parts of arachidonic acid, 4-6 parts of docosahexaenoic acid, 4-6 parts of compound vitamins, and 0.28-0.35 parts of nucleotides; or it can be 605 parts of vegetable fat powder, 150 parts of compound amino acids, 118.577 parts of solid corn syrup, 50 parts of compound minerals, 20 parts of choline premix, 10 parts of arachidonic acid, 5 parts of docosahexaenoic acid, 5 parts of compound vitamins, and 0.323 parts of nucleotides.

[0022] In this invention, based on 1000 parts by weight of infant amino acid formula powder, the compound amino acid preferably comprises the following components in parts by weight: 10-40 parts L-glutamine, 10-40 parts L-leucine, 10-40 parts L-lysine acetate, 10-40 parts L-aspartic acid, 5-35 parts L-proline, 5-35 parts L-isoleucine, 5-35 parts L-valine, 5-35 parts L-tyrosine, 5-25 parts L-threonine, 1-20 parts L-phenylalanine, 1-20 parts L-serine, 1-20 parts L-alanine, 1-20 parts L-histidine, 1-20 parts L-arginine, 1-20 parts glycine, 1-15 parts L-cysteine, 1-15 parts L-tryptophan, and 1-10 parts L-methionine. The following ingredients may be present: L-glutamine 15-25 parts, L-leucine 10-20 parts, L-lysine acetate 10-20 parts, L-aspartic acid 8-16 parts, L-proline 10-18 parts, L-isoleucine 8-14 parts, L-valine 8-14 parts, L-tyrosine 8-14 parts, L-threonine 5-10 parts, L-phenylalanine 3-8 parts, L-serine 3-8 parts, L-alanine 1-7 parts, L-histidine 1-7 parts, L-arginine 1-6 parts, glycine 1-5 parts, L-cysteine ​​1-5 parts, and L-tryptophan 1-4 parts. The following ingredients are listed: L-glutamine 23 parts, L-leucine 16 parts, L-lysine acetate 15 parts, L-aspartic acid 12 parts, L-proline 11 parts, L-isoleucine 9.6 parts, L-valine 9.6 parts, L-tyrosine 9 parts, L-threonine 7.6 parts, L-phenylalanine 6.9 parts, L-serine 6.3 parts, L-alanine 5.2 parts, L-histidine 3.6 parts, L-arginine 3.2 parts, glycine 3.2 parts, L-cysteine ​​3 parts, L-tryptophan 3 parts, and L-methionine 2.8 parts.

[0023] Using a compound amino acid as the sole source of protein not only ensures the nutritional needs of the protein but also completely avoids allergens. This provides a safe and reliable "gold standard" nutritional support for infants with severe cow's milk protein allergy, multiple food protein allergies, or even those who are intolerant to extensively hydrolyzed formula. In this embodiment of the invention, the compound amino acid was prepared by Wuxi Jinghai Amino Acid Co., Ltd.

[0024] In this invention, based on 1000 parts by weight of infant amino acid formula powder, the plant fat powder preferably comprises the following components in parts by weight: 170-250 parts of solid corn syrup, 80-120 parts of maltodextrin, 55-85 parts of medium-chain triglycerides, 50-70 parts of 1,3-dioleoyl-2-palmitoyl triglycerides, 40-60 parts of coconut oil, 42-57 parts of sunflower seed oil, 1-10 parts of flaxseed oil, 1-10 parts of mono- and diglycerides of fatty acids, 30-50 parts of sodium octenyl succinate starch, 0.5-2.0 parts of sodium L-ascorbate, 0.01-0.1 parts of mixed tocopherol concentrate, and 0.01-0.05 parts of ascorbate palmitate; or 200-230 parts of solid corn syrup, 90-110 parts of maltodextrin, 60-80 parts of medium-chain triglycerides, and 1,3-dioleoyl-2-palmitoyl triglycerides. The composition includes 55-65 parts of 2-palmitoyl triglyceride, 45-55 parts of coconut oil, 48-52 parts of sunflower seed oil, 5-10 parts of linseed oil, 1-5 parts of mono- and diglyceride fatty acid esters, 35-45 parts of sodium octenyl succinate starch, 1-1.5 parts of sodium L-ascorbate, 0.04-0.08 parts of mixed tocopherol concentrate, and 0.02-0.04 parts of ascorbate palmitate; it can also be composed of 209.05 parts of solid corn syrup, 103 parts of maltodextrin, 73 parts of medium-chain triglycerides, 59 parts of 1,3-dioleoyl-2-palmitoyl triglyceride, 56 parts of coconut oil, 51 parts of sunflower seed oil, 42 parts of sodium octenyl succinate starch, 7 parts of linseed oil, 3 parts of mono- and diglyceride fatty acid esters, 1.7 parts of sodium L-ascorbate, 0.2 parts of mixed tocopherol concentrate, and 0.05 parts of ascorbate palmitate. The 1,3-dioleoyl-2-palmitoylglycerol mimics the fat structure of breast milk, helping to improve the absorption efficiency of fat and calcium and reduce calcium soap formation, thus more closely resembling the physiological state of breastfeeding in terms of nutrient absorption, stool consistency, and abdominal comfort. The mixed tocopherol concentrate is a natural vitamin E used as an antioxidant. In this embodiment of the invention, the plant fat powder was prepared by Dalian Yinuo Biotechnology Co., Ltd.

[0025] In this invention, based on 1000 parts by weight of infant amino acid formula powder, the compound minerals preferably comprise the following components by weight: potassium 5-6.75 parts, magnesium 0.457-0.618 parts, iron 0.0585-0.079 parts, zinc 0.053-0.072 parts, calcium 4.01-5.43 parts, selenium 0.0002025-0.000304 parts, sodium 0.95-1.29 parts, phosphorus 2.51-3.395 parts, chlorine 3.36-4.545 parts, chromium 0.0001215-0.000198 parts, manganese 0.00255-0.00425 parts, and copper 0.003315-0.005525 parts; potassium can be 5.4-6.15 parts, ... Magnesium 0.5~0.58 parts, iron 0.06~0.07 parts, zinc 0.06~0.07 parts, calcium 4.5~5.0 parts, selenium 0.0002~0.00028 parts, sodium 1.0~1.1 parts, phosphorus 3.0~3.2 parts, chlorine 3.5~4.0 parts, chromium 0.00013~0.00017 parts, manganese 0.003~0.004 parts and copper 0.004~0.005 parts; it can also be potassium 5.9 parts, magnesium 0.5375 parts, iron 0.069 parts, zinc 0.0625 parts, calcium 4.72 parts, selenium 0.00253 parts, sodium 1.12 parts, phosphorus 2.95 parts, chlorine 3.955 parts, chromium 0.0001595 parts, manganese 0.0034 parts and copper 0.00442 parts. The potassium compound source preferably includes potassium chloride and / or potassium citrate. The magnesium compound source is preferably magnesium sulfate. The iron compound source is preferably ferric pyrophosphate. The zinc compound source is preferably zinc sulfate. The calcium compound source is preferably tricalcium phosphate and / or calcium carbonate. The selenium compound source is preferably sodium selenite. The sodium compound source is preferably disodium hydrogen phosphate. The phosphorus compound source is preferably tricalcium phosphate and / or disodium hydrogen phosphate. The chlorine compound source is preferably potassium chloride. The manganese compound source is preferably manganese sulfate. The copper compound source is preferably copper sulfate. The remaining components of the compound minerals in the infant amino acid formula powder are excipients. In this embodiment of the invention, the compound minerals are prepared by Columbia Nutrition Suzhou Co., Ltd.

[0026] In this invention, based on 1000 parts by weight of infant amino acid formula powder, the choline premix comprises the following components in parts by weight: 0.516-0.696 parts inositol, 0.36-0.49 parts taurine, 1.676-2.268 parts choline, and 0.1636-0.2214 parts L-carnitine; or 0.54-0.62 parts inositol, 0.40-0.45 parts taurine, 0.17-0.21 parts choline, and 1.8-2.1 parts L-carnitine; or 0.606 parts inositol, 0.424 parts taurine, 1.972 parts choline, and 0.192 parts L-carnitine. The remaining mass of the choline premix in the infant amino acid formula powder is an excipient. In this embodiment of the invention, the choline premix is ​​prepared by Columbia Nutrition Products (Suzhou) Co., Ltd.

[0027] In this invention, based on 1000 parts by weight of infant amino acid formula powder, the compound vitamins comprise the following components in parts by weight: Vitamin A 0.004685~0.00634 parts, Vitamin D 0.000146~0.000219 parts, Vitamin K1 0.000625~0.000845 parts, Vitamin B1 0.00635~0.0086 parts, Vitamin B2 0.0089~0.012 parts, Vitamin B6 0.0053~0.0072 parts, Niacin 0.047~0.064 parts, Folic Acid 0.00097~0.001315 parts, Pantothenic Acid 0.03925~0.0531 parts, Biotin 0.000145~0.000217 parts, Vitamin C 1.405~1.9 parts, Vitamin E 0.1035~0.1395 parts, vitamin B12 0.00001575~0.00002625 parts, and iodine 0.00107~0.00178 parts; it can also contain vitamin A 0.0050~0.0060 parts, vitamin D3 0.00018~0.000200 parts, vitamin K1 0.0007~0.000800 parts, vitamin B1 0.0070~0.0080 parts, vitamin B2 0.0092~0.011 parts, and vitamin B6 0.0060~0.0070 parts, niacin 0.050~0.06 parts, folic acid 0.0001~0.0012 parts, pantothenic acid 0.040~0.050 parts, biotin 0.00016~0.000200 parts, vitamin C 1.6~1.8 parts, vitamin E 0.11~0.1300 parts, vitamin B12 0.000018~0.000022 parts, and iodine 0.0012~0.0016 parts; or vitamin A 0.005515 parts, vitamin D3 0.0001825 parts, vitamin K1 0.000735 parts, vitamin B1 0.00745 parts, vitamin B2 0.01045 parts, and vitamin B6 The formula contains 0.00625 parts of niacin, 0.0555 parts of folic acid, 0.001145 parts of pantothenic acid, 0.04615 parts of biotin, 0.000181 parts of vitamin C, 1.65 parts of vitamin E, 0.1215 parts of vitamin B12, and 0.001425 parts of iodine. The remaining components of the compound vitamins in the infant amino acid formula are excipients. In this embodiment of the invention, the compound vitamins were prepared by Columbia Nutrition Products (Suzhou) Co., Ltd.

[0028] In this invention, the nucleotide comprises the following components in parts by weight: 0.01-0.2 parts of 5'-adenosine monophosphate, 0.05-0.2 parts of 5'-cytidine monophosphate, 0.05-0.15 parts of disodium 5'-uridine monophosphate, 0.01-0.1 parts of disodium 5'-guanylate, and 0.001-0.02 parts of disodium 5'-inosine monophosphate; or 0.01-0.1 parts of 5'-adenosine monophosphate and 0.001-0.02 parts of 5'-cytidine monophosphate. 1-0.2 parts, 0.05-0.12 parts of 5'-uridine monophosphate disodium, 0.03-0.08 parts of 5'-guanylate disodium, and 0.005-0.015 parts of 5'-inosinate disodium; or 0.05 parts of 5'-adenosine monophosphate, 0.119 parts of 5'-cytidine monophosphate, 0.088 parts of 5'-uridine monophosphate disodium, 0.057 parts of 5'-guanylate disodium, and 0.009 parts of 5'-inosinate disodium. In this embodiment of the invention, the nucleotides were prepared by Dalian Evolution Biotechnology Co., Ltd.

[0029] This invention provides a method for preparing the aforementioned infant amino acid formula powder, comprising the following steps: A portion of solid corn syrup, Bifidobacterium longum subsp. infantis M-63, 3'-sialic acid lactose sodium nucleotide, fructooligosaccharide, lactose-N-neotetrasaccharide, compound vitamins, compound minerals and docosahexaenoic acid were dry premixed to obtain the first mixture. The premix, the remaining solid corn syrup, 2'-fucosylated lactose, arachidonic acid, galactooligosaccharides, choline premix, and compound amino acids are dry-mixed to obtain a second mixture; The second mixture and vegetable fat powder are dry-mixed to obtain an infant amino acid formula powder.

[0030] In this invention, the dry premixing or dry mixing method preferably includes manual stirring or mixing with a mixer. In this embodiment, a mixer is used for mixing. During mixing, the speed of the mixer is preferably 40-60 r / min, and can be 56 r / min. The mixing time is preferably 3-8 min, and can be 5 min.

[0031] In this invention, after the final dry powder mixing, product packaging is also included. The packaging container is preferably a tin-plated iron can. The product packaging method preferably involves sending the filled tin-plated iron can to a magnetic capping machine for capping, nitrogen filling, and sealing; the sealed iron can is then conveyed to the outer packaging room, where it is coded, flipped, capped, boxed, and stacked on a conveyor belt.

[0032] This invention provides the application of the synbiotic in the preparation of amino acid formula powder for infants with protein allergies.

[0033] In this invention, the infants and young children preferably include individuals allergic to at least one of the following: food proteins, breast milk proteins, and extensively hydrolyzed formula milk powder. The food proteins include common infant foods such as milk, eggs, and rice cereal. The infants and young children include newborns to children over 6 years of age. The applicable symptoms for these infants and young children include severe protein allergy and / or gastrointestinal dysfunction.

[0034] Compared to existing amino acid-based infant formula products, the core feature of the amino acid-based infant formula for regulating protein allergies provided by this invention lies in the introduction of an advanced synbiotic system. This involves the innovative and scientific blending of traditional prebiotics (such as galactooligosaccharides / fructooligosaccharides), human milk oligosaccharides (HMOs), and specific probiotics. Studies have shown that infants with food protein allergies often experience gut microbiota imbalance and impaired intestinal barrier function. The innovative synergistic formula used in this infant amino acid formula for regulating protein allergies works synergistically: prebiotics and human milk oligosaccharides selectively promote the proliferation of beneficial bacteria (such as Bifidobacteria) in the gut and inhibit the growth of pathogens; simultaneously, human milk oligosaccharides can directly block the adhesion of pathogens to the intestinal mucosa and support the normal development and regulation of the immune system; while the added active probiotics can further colonize the gut, working with the aforementioned components to repair the gut microbiota balance, enhance intestinal barrier function, and regulate the immune response towards Th1 / Treg, thereby helping to reduce the severity of allergic reactions from the fundamental pathway of the microbiota-immune axis and potentially promoting the early establishment of oral immune tolerance. This design transcends the traditional scope of amino acid formulas that only provide "allergy-free nutrition," giving the product the added value of actively regulating gut health and immune function, representing a new direction in the research and development of special medical purpose formula foods. Therefore, developing a lactose-free amino acid formula food suitable for infants with food protein allergies that is not only nutritionally complete and possesses an innovative synergistic system, but also uses advanced dry processing technology to ensure the bioactivity of nutrients has significant clinical and market value. This project aims to provide a safer, more effective, and novel nutritional solution for infants with food allergies in my country, offering both nutritional support and microecological-immune regulation functions, through dual innovation in ingredient formulation and processing technology.

[0035] The following detailed description, in conjunction with embodiments, illustrates the present invention of a milk powder, a synthetic protein formula for regulating food protein allergy, an infant amino acid formula powder, and its preparation method. However, these descriptions should not be construed as limiting the scope of protection of the present invention.

[0036] Example 1 A type of infant formula containing biosimilars that regulates food protein allergies comprises the following components by weight: 18g of galactooligosaccharides, 8.0g of 2'-fucosylated lactose, 2.0g of fructooligosaccharides, 1.4g of sodium 3'-sialyl lactose, 2.7g of lactose-N-neotetrasaccharide, and 1g of Bifidobacterium longum subsp. infantis M-63.

[0037] Example 2 An amino acid formula powder for infants and young children that regulates food protein allergies 1. Accurately weigh the following components: 605g vegetable fat powder, 150g compound amino acids, 121.577g solid corn syrup, 50g compound minerals, 20g choline premix, 18g galactooligosaccharides, 10g arachidonic acid, 8.0g 2'-fucosylated lactose (2'-FL), 5.0g docosahexaenoic acid, 5.0g compound vitamins, 2.7g lactose-N-neotetrasaccharide (LNnt), 2.0g fructooligosaccharides, 1.4g 3'-sialic acid lactose sodium salt (3'-SL), 1g Bifidobacterium longum subsp. infantis M-63, and 0.323g nucleotides.

[0038] The vegetable fat powder contains: 209.05g of solid corn syrup, 103g of maltodextrin, 73g of medium-chain triglycerides, 59g of 1,3-dioleoyl-2-palmitoyl triglycerides, 56g of coconut oil, 51g of sunflower seed oil, 42g of sodium octenyl succinate starch, 7g of flaxseed oil, 3g of mono- and diglycerides of fatty acids, 1.7g of sodium L-ascorbate, 0.2g of mixed tocopherol concentrate, and 0.05g of ascorbate palmitate. The compound amino acid contains: L-glutamine 23g, L-leucine 16g, L-lysine acetate 15g, L-aspartic acid 12g, L-proline 11g, L-isoleucine 9.6g, L-valine 9.6g, L-tyrosine 9g, L-threonine 7.6g, L-phenylalanine 6.9g, L-serine 6.3g, L-alanine 5.2g, L-histidine 3.6g, L-arginine 3.2g, glycine 3.2g, L-cysteine ​​3g, L-tryptophan 3g, and L-methionine 2.8g.

[0039] The compound minerals include: potassium (compound source: potassium chloride) 5.9g, magnesium (compound source: magnesium sulfate) 0.5375g, iron (compound source: ferric pyrophosphate) 0.069g, zinc (compound source: zinc sulfate) 0.0625g, calcium (compound source: tricalcium phosphate, calcium carbonate) 4.72g, selenium (compound source: sodium selenite) 0.00253g, sodium (compound source: disodium hydrogen phosphate) 1.12g, phosphorus (compound source: tricalcium phosphate, disodium hydrogen phosphate) 2.95g, chlorine (compound source: potassium chloride) 3.955g, chromium (compound source: chromium chloride) 0.0001595g, manganese (compound source: manganese sulfate) 0.0034g, copper (compound source: copper sulfate) 0.00442g, and excipients 30.6754905g.

[0040] The choline premix contains: inositol 0.606g, taurine 0.424g, choline (compound source: choline tartrate) 1.972g, L-carnitine (compound source: L-carnitine tartrate) 0.192g, and excipients 16.806g.

[0041] The compound vitamin contains: Vitamin A (compound source: retinyl acetate) 0.005515g, Vitamin D3 (compound source: cholecalciferol) 0.0001825g, Vitamin K1 (compound source: ) 0.000735g, Vitamin B1 (compound source: thiamine hydrochloride) 0.00745g, Vitamin B2 (compound source: riboflavin) 0.01045g, Vitamin B6 (compound source: pyridoxine hydrochloride) 0.00625g, Niacin (compound source: nicotinamide) 0.0555g, Folic acid (compound source: folic acid (10%)) 0.001145g, Pantothenic acid (compound source: D-calcium pantothenate) 0.04615g, Biotin (compound source: D-biotin) 0.000181g, and Vitamin C (compound source: L-sodium ascorbate). 1.65g, Vitamin E (compound source: dL-α-tocopherol acetate (50%)) 0.1215g, Vitamin B12 (compound source:) 0.000021g and Iodine (compound source: potassium iodide) 0.001425g, excipients 3.2028455g.

[0042] The nucleotides contain: 0.05g of 5'-adenosine monophosphate, 0.119g of 5'-cytidine monophosphate, 0.088g of disodium 5'-uridine monophosphate, 0.057g of disodium 5'-guanylate, and 0.009g of disodium 5'-inosine monophosphate.

[0043] 2. Preparation method (1) Acceptance of raw materials and auxiliary materials: When raw materials enter the factory, they shall be sampled and inspected in accordance with national standards or corresponding enterprise internal control standards.

[0044] (2) Ingredient weighing: Raw materials that have passed the incoming inspection are requisitioned according to the production plan. After requisition, the outer packaging is removed in the unpacking room, and then the inner packaging is cleaned of dust in the cargo shower. The materials to be used are weighed according to the production plan.

[0045] (3) Premixing: First, put solid corn syrup into the premixer, then add Bifidobacterium infantis subsp. M-63, 3'-sialic acid lactose sodium nucleotide, fructooligosaccharide, lactose-N-neotetrasaccharide, compound vitamins, compound minerals and docosahexaenoic acid in sequence. After mixing evenly, it becomes the premix. The speed of the premixer is set to 56 r / min and the mixing time is 5 min.

[0046] (4) Dry mixing: Solid corn syrup, the above premix, 2'-fucosylated lactose, arachidonic acid, galactooligosaccharide, choline premix, and compound amino acids are added to the dry mixer in sequence. Finally, vegetable fat powder is added and mixed evenly to obtain the intermediate product. The dry mixer speed is set to 56 r / min and the mixing time is 5 min.

[0047] (5) Packaging: Intermediate products fall through a metal detector to the filling machine, ready for filling. Tin-plated iron cans are transported to the automatic filling machine via an empty can conveyor line for product filling. The total weight is weighed by an automatic checkweigher, and iron cans that do not meet the weight requirements are rejected. Iron cans that meet the weight requirements are conveyed to the magnetic capping machine for capping, nitrogen filling, and sealing. The sealed iron cans continue to be conveyed to the outer packaging room, where they are coded, flipped, capped, boxed, and stacked on the conveyor belt.

[0048] Example 3 animal experiments 1. Experimental model construction: Female BALB / c mice, 3-4 weeks old, SPF grade. A β-lactoglobulin (BLG)-induced food allergy mouse model was established.

[0049] Establishment of a food allergy mouse model: On days 0, 7, 14, and 21, each mouse was intraperitoneally injected with a mixed emulsion of 50 μg BLG and 2 mg aluminum hydroxide adjuvant (dissolved in 200 μL PBS) to induce a systemic TH2 immune response and specific IgE production. On day 28, 20 mg of BLG (dissolved in saline) was administered orally by gavage to elicit an acute allergic reaction.

[0050] 2. Experimental group and dosage design: Normal control group: Both intraperitoneal injection and oral gavage were given an equal volume of PBS or physiological saline.

[0051] Food allergy mouse model group (BLG): The mice were subjected to the above-mentioned BLG sensitization and challenge, without any prebiotic intervention.

[0052] Prebiotic composition intervention group: Patients were fed different formulations of prebiotic compositions according to Table 1. Oral administration was administered once daily from day 0 (the day of initial sensitization) to day 28 (the day of attack). The intervention dose was 380 mg / kg / day (dissolved in sterile water or 0.5% sodium carboxymethyl cellulose solution).

[0053] Table 1. Proportions of Prebiotic Compositions

[0054] Note: The ratio of different components is the mass ratio.

[0055] 3. Testing Items Allergy symptom scoring: Within 1 hour of the attack, scores are given based on phenotypes (scratching, hair piloerection, bradykinesia, difficulty breathing, etc.). The scoring criteria are shown in Table 2. Table 2 Allergy Symptom Scoring Table

[0056] Serological markers: BLG-specific IgE, IgG1, and mast cell protease-1 (mMCP-1) were detected by enzyme-linked immunosorbent assay. 4. Experimental Results: The normal control group had the lowest score (0 points), indicating no allergic reaction. The BLG group had the highest score (3 points), indicating the strongest allergic reaction. The GOS / FOS group, the 2'-FL deficiency group, and the LNnT deficiency group had relatively high scores (2 points), indicating that these groups still had significant allergies. The 3'-SL deficiency group, the prebiotic group, and the synbiotic group had relatively low scores (1 point), with the synbiotic group having the lowest score (0 or 1 point), indicating that it had the best anti-allergic effect. Therefore, the synbiotic group performed best in alleviating allergy symptoms.

[0057] The normal control group had extremely low IgE, IgG1 was 0, and mMCP-1 was at baseline, confirming the absence of allergic reactions. In contrast, the BLG model group had the highest IgE, IgG1, and mMCP-1 levels, indicating a typical allergic reaction. The GOS / FOS group had IgE, IgG1, and mMCP-1 levels very close to those of the BLG group, suggesting that the GOS / FOS group failed to suppress allergic reactions and may have exacerbated them. The IgE level in the group lacking specific HMOs was significantly lower than that in the BLG and GOS / FOS groups, but higher than that in the prebiotic / synbiotic group; the IgG1 level was slightly lower than that in the BLG group, but remained at a high level. The mMCP-1 level was lower than that in the BLG group, but higher than that in the prebiotic / synbiotic group. Removing any HMO (2'-FL, LNnT, 3'-SL) from the complete synbiotic formula led to a decrease in overall protective efficacy. The synchronous but moderate decrease in all three levels indicates that each HMO contributes to inhibiting the complete allergic chain (IgE→IgG1→mMCP-1). Among them, the decreases in IgG1 and mMCP-1 appeared to be more pronounced in the 3'-SL deficiency group. Prebiotic intervention effectively inhibited sensitization (IgE) and Th2 response (IgG1), thereby mitigating the effector phase response (mMCP-1) and showing a protective trend. Synbiotic intervention exhibited a synergistic enhancing effect. It most effectively blocked the initiation of allergy (inhibiting IgE), strongly corrected Th2 immune shift (significantly reducing IgG1), and thus maximally inhibited the terminal effect (significantly reducing mMCP-1). The three indicators showed a highly consistent and maximum decrease.

[0058] By comprehensively analyzing IgE, IgG1, mMCP-1, and allergy symptom scores, it can be clearly concluded that synbiotic formulations containing specific HMOs (2'-FL, LNnT, 3'-SL) are the most effective strategy for inhibiting the entire allergic process from sensitization to onset.

[0059] Example 4 In vitro simulation verification 1. Research Subjects Ten healthy, vaginally delivered, breastfed infants aged 6-12 months with no antibiotic intake were recruited and their stool samples were collected.

[0060] 2. Experimental group and dosage design: Prebiotic group A consists of GOS + FOS (9:1, by mass); The prebiotic B group consisted of GOS+FOS+2'-FL+LNnT+3'-SL (9:1:4:1.25:0.7, by mass). Synbiotic C group: GOS+FOS+2'-FL+LNnT+3'-SL+probiotics (9:1:4:1.25:0.7:0.5), the probiotic is Bifidobacterium longum subsp. infantis M-63; 3. Test Methods 1) In vitro colonic fermentation A suspension of fecal microbiota from healthy infants, fermented in an anaerobic culture medium (such as YCFA, GAM, etc.), under anaerobic conditions at 37°C. o Samples were taken 48 hours after fermentation, and the content of short-chain fatty acids was determined by chromatography. The composition of fecal microbiota before and after fermentation was analyzed by 16S rRNA sequence analysis.

[0061] 4. Test Results Table 3 Results of bacterial abundance and SCFA content determination

[0062] After 24 hours of fermentation, the short-chain fatty acids (acetic acid, propionic acid, and butyric acid) in the fermentation broth of each group were quantitatively analyzed, and the results are shown in Table 3. The acetic acid content in the synbiotic group was significantly higher than that in the prebiotic A group and the prebiotic B group. The prebiotic mixture provided a richer fermentation substrate for the intestinal flora, while the added probiotic M-63 further synergistically promoted the metabolic activity of acid-producing bacteria. Similar to the trend in acetic acid, the synbiotic group also showed a significant advantage in the production of propionic acid and butyric acid. In particular, butyric acid, as a SCFA that is crucial for intestinal barrier and immune regulation, saw its production in the synbiotic group reach a peak at 48 hours, significantly higher than that in the prebiotic mixture group and the prebiotic A group.

[0063] Regarding the abundance of Bifidobacteria, after 48 hours of fermentation, the relative abundance of Bifidobacteria in the synbiotic group increased most significantly, followed by the prebiotic B group. This directly demonstrates that the addition of Bifidobacterium longum subsp. infantis M-63, supported by a prebiotic mixture "tailor-made" for it (mimicking the structure of human milk oligosaccharides), achieved optimal colonization and proliferation effects, forming a synergistic effect of "1+1>2".

[0064] The results of the above examples demonstrate that synbiotics exhibit the best effects: the synbiotic combination of "prebiotic mixture (GOS / FOS / HMOs) + Bifidobacterium longum subsp. infantis M-63" is most effective in promoting the production of beneficial metabolites and shaping a healthy gut microbiota structure. This group produced the highest total amount of short-chain fatty acids (SCFAs) and the highest proportion of butyrate, while also showing the most significant proliferation of Bifidobacteria. The structural complexity of prebiotics is positively correlated with their function. Comparing the two prebiotic combinations, it was found that the complex mixture containing human milk oligosaccharides (HMOs) such as 2'-FL, LNnT, and 3'-SL (Group B) was superior to the traditional GOS / FOS (9:1) combination in regulating gut microbiota and acid production.

[0065] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A synbiotic for regulating protein allergy, characterized in that, The components include the following parts by weight: 10-30 parts of galactooligosaccharide, 1-3 parts of fructooligosaccharide, 5-15 parts of 2'-fucosylated lactose, 1-3 parts of lactose-N-neotetrasaccharide, 1-2 parts of sodium 3'-sialic acid lactose, and 0.1-5 parts of Bifidobacterium longum subsp. infantis M-63.

2. The synbiotic for regulating protein allergy according to claim 1, characterized in that, The components include the following parts by weight: 15-20 parts of galactooligosaccharides, 1.5-2.5 parts of fructooligosaccharides, 7-10 parts of 2'-fucosylated lactose, 2.5-3.0 parts of lactose-N-neotetrasaccharide, 1.2-1.6 parts of sodium 3'-sialylated lactose, and 0.5-1.2 parts of Bifidobacterium longum subsp. infantis M-63.

3. The synbiotic for regulating protein allergy according to claim 1 or 2, characterized in that, The components include the following parts by weight: 18 parts of galactooligosaccharides, 2.0 parts of fructooligosaccharides, 8 parts of 2'-fucosylated lactose, 2.7 parts of lactose-N-neotetrasaccharide, 1.4 parts of sodium 3'-sialyl lactose, and 1 part of Bifidobacterium longum subsp. infantis M-63.

4. An amino acid formula powder for infants and young children that regulates protein allergy, characterized in that, Includes the synbiotic as described in any one of claims 1 to 3 and the following components in parts by weight: 500-700 parts vegetable fat powder, 130-160 parts compound amino acids, 110-140 parts solid corn syrup, 40-60 parts compound minerals, 10-30 parts choline premix, 5-15 parts arachidonic acid, 2.5-7.5 parts docosahexaenoic acid, 2.5-7.5 parts compound vitamins, and 0.20-0.40 parts nucleotides; One part by weight of the ingredients is based on one part by weight of Bifidobacterium longum subsp. infantis M-63.

5. The infant amino acid formula powder according to claim 4, characterized in that, It includes the following ingredients by weight: 580-620 parts vegetable fat powder, 145-155 parts compound amino acids, 120-130 parts solid corn syrup, 45-55 parts compound minerals, 15-25 parts choline premix, 8-12 parts arachidonic acid, 4-6 parts docosahexaenoic acid, 4-6 parts compound vitamins, and 0.28-0.35 parts nucleotides.

6. The infant amino acid formula powder according to claim 4, characterized in that, Based on 1000 parts by weight of infant amino acid formula powder, the compound amino acid comprises the following components in parts by weight: 10-40 parts L-glutamine, 10-40 parts L-leucine, 10-40 parts L-lysine acetate, 10-40 parts L-aspartic acid, 5-35 parts L-proline, 5-35 parts L-isoleucine, 5-35 parts L-valine, 5-35 parts L-tyrosine, 5-25 parts L-threonine, 1-20 parts L-phenylalanine, 1-20 parts L-serine, 1-20 parts L-alanine, 1-20 parts L-histidine, 1-20 parts L-arginine, 1-20 parts glycine, 1-15 parts L-cysteine, 1-15 parts L-tryptophan, and 1-10 parts L-methionine.

7. The infant amino acid formula powder according to any one of claims 4 to 6, characterized in that, Based on 1000 parts by weight of infant amino acid formula powder, the plant fat powder comprises the following parts by weight. Composition: 170-250 parts solid corn syrup, 80-120 parts maltodextrin, 55-85 parts medium-chain triglycerides, 50-70 parts 1,3-dioleoyl-2-palmitoyl triglycerides, 40-60 parts coconut oil, 42-57 parts sunflower seed oil, 1-10 parts linseed oil, 1-10 parts mono- and diglycerides of fatty acids, 30-50 parts sodium octenyl succinate starch, 0.5-2.0 parts sodium L-ascorbate, 0.01-0.1 parts mixed tocopherol concentrate, and 0.01-0.05 parts ascorbate palmitate. The compound minerals comprise the following components by weight: potassium 5-6.75 parts, magnesium 0.457-0.618 parts, iron 0.0585-0.079 parts, zinc 0.053-0.072 parts, calcium 4.01-5.43 parts, selenium 0.0002025-0.000304 parts, sodium 0.95-1.29 parts, phosphorus 2.51-3.395 parts, chlorine 3.36-4.545 parts, chromium 0.0001215-0.000198 parts, manganese 0.00255-0.00425 parts, and copper 0.003315-0.005525 parts; The choline premix comprises the following components by weight: 0.516-0.696 parts inositol, 0.36-0.49 parts taurine, 0.1636-0.2214 parts choline, and 1.676-2.268 parts L-carnitine; The compound vitamins comprise the following components by weight: Vitamin A 0.004685~0.00634 parts, Vitamin D3 0.000146~0.000219 parts, Vitamin K1 0.000625~0.000845 parts, Vitamin B1 0.00635~0.0086 parts, Vitamin B2 0.0089~0.012 parts, Vitamin B6 0.0053~0.0072 parts, Niacin 0.047~0.064 parts, Folic Acid 0.00097~0.001315 parts, Pantothenic Acid 0.03925~0.0531 parts, Biotin 0.000145~0.000217 parts, Vitamin C 1.405~1.9 parts, Vitamin E 0.1035~0.1395 parts, and Vitamin B12. 0.00001575~0.00002625 parts and iodine 0.00107~0.00178 parts; The nucleotides comprise the following components in parts by weight: 0.01-0.2 parts of 5'-adenosine monophosphate, 0.05-0.2 parts of 5'-cytidine monophosphate, 0.05-0.15 parts of disodium 5'-uridine monophosphate, 0.01-0.1 parts of disodium 5'-guanylate, and 0.001-0.02 parts of disodium 5'-inosinate.

8. A method for preparing the infant amino acid formula powder according to any one of claims 4 to 6, characterized in that, Includes the following steps: A portion of solid corn syrup, Bifidobacterium longum subsp. infantis M-63, 3'-sialic acid lactose sodium nucleotide, fructooligosaccharide, lactose-N-neotetrasaccharide, compound vitamins, compound minerals and docosahexaenoic acid were dry premixed to obtain the first mixture. The premix, the remaining solid corn syrup, 2'-fucosylated lactose, arachidonic acid, galactooligosaccharides, choline premix, and compound amino acids are dry-mixed to obtain a second mixture; The second mixture and vegetable fat powder are dry-mixed to obtain an infant amino acid formula powder.

9. The use of the synbiotic as described in any one of claims 1 to 3 in the preparation of amino acid formula powder for infants with protein allergies.

10. The application according to claim 9, characterized in that, The infants and young children mentioned include those who are allergic to at least one of the following: food proteins, breast milk proteins, and extensively hydrolyzed formula milk powder.

Images